Exploring Novel Delivery Systems to Advance NMIBC Treatment
Karim Chamie, MD, MSHS, discusses how innovative non–muscle invasive bladder cancer (NMIBC) delivery systems such as TAR-200 offer targeted, less toxic treatment options, showing promise for high-risk patients with improved efficacy and patient tolerance through localized drug administration.
EP. 1: Drug Delivery Systems in NMIBC
March 10th 2025An expert discusses how non–muscle invasive bladder cancer (NMIBC) treatment involves evolving delivery systems, transitioning from traditional systemic and intravesical approaches to advanced targeted technologies. Current research focuses on innovative platforms such as nanoparticle carriers, thermosensitive hydrogels, and personalized molecular delivery mechanisms to improve therapeutic efficacy and minimize systemic toxicity.
EP. 2: TAR-200 for Treatment of BCG-Unresponsive, High-Risk NMIBC
March 17th 2025An expert discusses how the SunRISe-1 phase 2b trial, presented at the European Society for Medical Oncology 2024 Congress (ESMO 2024), evaluated TAR-200 alone and with cetrelimab in BCG-unresponsive, high-risk non–muscle invasive bladder cancer (NMIBC). TAR-200 monotherapy achieved an 84% complete response rate, with most adverse events being mild to moderate. The combination therapy showed higher rates of severe adverse events. TAR-200 is particularly promising for patient’s ineligible for or refusing radical cystectomy.
EP. 3: Adoption of Emerging Delivery Systems and Future Outlook for NMIBC
March 24th 2025An expert discusses how TAR-200 shows promise for non–muscle invasive bladder cancer (NMIBC) treatment, with medical professionals optimistic about its targeted delivery, potentially improved outcomes, and transformative approach to bladder cancer management.
